Clinical Trial Update: Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of PTK787/ZK222584 for metastatic neuroendocrine tumors has completed, per this clinical trial update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• PTK787/ZK222584 (vatalanib)

Snippet

Sponsor: Louisiana State University Health Sciences Center in New Orleans | Conditions: Metastatic Neuroendocrine Tumors | Phase 2 | Status: COMPLETED